Kriya Therapeutics develops gene therapies for conditions affecting millions of people globally, with a focus on making these therapies accessible. The company targets areas of high unmet need, utilizing innovative gene therapy approaches.

Kriya Therapeutics

IPhone / Mobile Compatible

Viewport Meta

SSL by Default

Google Tag Manager

Apple Mobile Web Clips Icon

Google Analytics

Content Delivery Network

WordPress

Global Site Tag

President Manufacturing and Technical Operations

Britt Petty

President, Research and Development

Melissa Rhodes

President, Technology

Nachi Gupta

Co-Founder & Vice Chairman

Roger Jeffs

Co-Founder and Chief Executive Officer

Shankar Ramaswamy

SVP Technical Operations

Mitch Lower

Healthcare

Andrea Pappas, Ph.D.

Associate Director, Quality Assurance

Brandy Bateman

Director of Process Sciences and Research Core

Charles Pugh

Associate Director

Chelsea Sullivan

Keith Manchester

Fraser Wright

Jeff Bird

Ma'an Muhsin

President and Chief Medical Officer

Scientific Co-Founder

Theresa Heah

Chief Medical Officer & President- Kriya Ophthalmology

Curt Herberts

President and COO

Chief Gene Therapy Officer

Katherine Eade

Chief Legal Officer

Western US Startups (Top 10K)

California Startups Founded in 2019

Health Care Companies With More Than $10M in Revenue (Top 10K)

West Coast Companies With More Than 50 Employees (Top 10K)

Kriya Therapeutics is a fully integrated platform company pioneering novel technologies and therapeutics in gene therapy. They have built a fully integrated engine that consolidates the critical infrastructure and technology needed to engineer, manufacture, characterize, and develop new gene therapies

Patient Square Capital

Series C - Kriya Therapeutics

Series B - Kriya Therapeutics

QVT Financial

Series A - Kriya Therapeutics

Transhuman Capital

Seed Round - Kriya Therapeutics

Palo Alto

California

United States

North America

Kriya Announces Publication of Preclinical Data for its Investigational AAV-FGF21 Gene Therapy Demonstrating Durable Reversal of Liver Fibrosis

Kriya Appoints Scientific Co-Founder J. Fraser Wright, Ph.D., as Chief Gene Therapy Officer

Gene Therapy Co. Taps Experienced Bioscience Legal Chief

Kriya Appoints Katherine Eade as Chief Legal Officer

KRIYA-825 ameliorates retinal degeneration in mice, study shows

Shankar Ramaswamy, M.D. on LinkedIn: For those of you in Baltimore at ASGCT this week, looking forward to…

Shankar Ramaswamy, M.D.’s Post

Developers in TED cruise toward phase III days in the sun; Tepezza to feel the chill?

Gene Therapy Global Market is Projected to Grow at a CAGR of ~19% by 2028, Predicts DelveInsight

A gene therapy aimed at treating Geographic Atrophy by inhibiting complement C3 and C5, administered as a one-time suprachoroidal injection.

A gene therapy for Thyroid Eye Disease that blocks IGF1 receptors, delivered through a one-time peribulbar injection.

A gene therapy for Diabetes, expressing insulin and glucokinase for durable glycemic control, delivered intramuscularly.

A gene therapy targeting NASH by expressing the native FGF21 protein, administered intramuscularly to reduce fibrosis and improve metabolic profile.

A gene therapy for Trigeminal Neuralgia, expressing a chemogenetically-gated ion channel, injected into the trigeminal nerve to reduce pain attacks.

A gene therapy for Focal Epilepsy, expressing a chemogenetically-gated ion channel, delivered directly into epileptic foci to minimize seizures.

India

Asia

Japan

Pakistan

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Oct 2, 2024 12:44 PM	c677ba6a
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Oct 2, 2024 12:44 PM	65c59ab8
crunchbase trigger	general	Nov 27, 2024 12:50 PM	3c3695ad
crunchbase profile	general	Nov 27, 2024 1:24 PM	bad350c6
li profile	general
translate crunchbase fundingrounds	general	Nov 27, 2024 2:00 PM	ffd2c988
peers	general	Oct 2, 2024 12:44 PM	d7ca4be8
news basic	general	Oct 2, 2024 12:44 PM	49827f90
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:KRIYATHERAPEUTICS

Kriya Therapeutics